Amgen is the world's largest independent biotechnology company by revenue and one of the world's leading biotechnology companies.
Amgen generated $36.8 billion in revenue in 2025, growing 10% year-over-year, making it the largest pure-play biotechnology company by revenue. The company's $28 billion acquisition of Horizon Therapeutics in 2023 transformed its rare disease portfolio, adding TEPEZZA for thyroid eye disease, KRYSTEXXA for uncontrolled gout, and UPLIZNA for neuromyelitis optica. Amgen's biosimilar business — with commercial launches across oncology, immunology, and neurology — generated over $2 billion in 2025 revenue and is a growing contributor to the company's revenue diversification. The KRAS-targeted cancer drug LUMAKRAS, bispecific antibodies Blincyto and Imdelltra, and the obesity drug MariTide in Phase 3 development represent the company's growth pipeline.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and platform capabilities
• Latest products, pipeline, and R&D programs
• M&A and partnership activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management
Table of Contents
1. Executive Summary
2. Company Overview
3. Strategic Directions
4. Financial Performance
5. SWOT Analysis
6. Technological Know-How and Key Products
7. M&A and Partnerships
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. Amgen — Key Financial Metrics 2023-2025
Table 2. Amgen — Revenue by Product 2023-2025
Table 3. Amgen — Revenue by Geography 2023-2025
Table 4. Amgen — R&D Investment 2023-2025
Table 5. Amgen — SWOT Analysis
Table 6. Amgen — Key Products and Pipeline 2025
Table 7. Amgen — M&A Activity 2020-2025
Table 8. Amgen — Key Management 2025
Table 9. Amgen — Strategic Priorities 2025-2030
